Under the contract, Fosun Industrial will distribute Atrium brands in China.
The new JV, which will operated under the FOSIUM Innovations name, will initially import, market and sell Pure Encapsulations products in the Chinese mainland market.
In addition, the products will be continued to be manufactured in the US and other existing Atrium brands will be launched subsequently.
Atrium will make an initial investment in the JV of $1m, for a participation of 49%.
Atrium Innovations president and CEO Pierre Fitzgibbon said the company’s JV with Fosun Pharma will provide needed local expertise and access to various distribution channels.
"Although we expect some revenues in 2013, our investment in this new market should be viewed as a long-term commitment where we believe we can distribute other brands of our portfolio," Fitzgibbon added.